 CAMBRIDGE, Mass., June 08, 2022 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that interim clinical data from the Phase 1 study of NTLA-2001, an investigational therapy in development for the treatment of transthyretin ATTR amyloidosis, will be shared in an oral presentation at the European Association for the Study of the Livers International Liver CongressTM 2022, taking place June 22 26 in London. 